Security key
87184Q107
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS)
CUSIP: 87184Q107
Q3 2022 13F Holders as of 30 Sep 2022
- Security type / class
- Equity / Common Stock, $0.001 par value
- Total 13F shares
- 881,719
- Total 13F value
- $5,679,000
- Share change
- -34,647,651
- SEC-reported price per share
- $6.44
- Number of holders
- 3
- Value change
- -$38,920,523
- Number of buys
- 1
- Number of sells
- 57
- Shares outstanding
- 27,995,500
Holder snapshot
6 signals
Security identity
1 source field
Report period
Q3 2022
Institutions
3
Top holders
3
SYRS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2022
Previous quarter: Q2 2022
Syros Pharmaceuticals, Inc. SEC filings
Syros Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87184Q107
Recent filing periods:
Ownership snapshot
Top reported holders of SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
30 Jun 2022
13F
Lead comparable stake: 22%
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 22%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Bain Capital Life Sciences Invest...
22%
Artal Group S.A.
14%
Ally Bridge Group (NY) LLC
12%
Flagship Pioneering, LLC
10%
VANGUARD GROUP INC
10%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
22%
|
$6,031,000
6,264,420 shares
|
— | 30 Jun 2022 |
| Artal Group S.A. |
13F
Company
|
14%
|
$3,851,000
4,000,000 shares
|
— | 30 Jun 2022 |
| Ally Bridge Group (NY) LLC |
13F
Company
|
12%
|
$3,239,000
3,364,895 shares
|
— | 30 Jun 2022 |
| Flagship Pioneering, LLC |
13F
Company
|
10%
|
$2,821,000
2,938,494 shares
|
— | 30 Jun 2022 |
| VANGUARD GROUP INC |
13F
Company
|
10%
|
$2,775,000
2,882,608 shares
|
— | 30 Jun 2022 |
| FMR LLC |
13F
Company
|
9.4%
|
$2,525,000
2,623,063 shares
|
— | 30 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
881,719
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2022 vs Q2 2022 Across Filers
Q2 2022 holders
58
Q3 2022 holders
3
Holder diff
-55
| Investor | Q2 2022 Shares | Q3 2022 Shares | Share Diff | Share Chg % | Q2 2022 value | Q3 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend